Figure - uploaded by David Balakirouchenane
Content may be subject to copyright.
Antitumor treatment regimen. “Other” antitumoral regimen included: vinorelbine, temozolomide–irinotecan regimen, sorafenib, regorafenib, sunitinib

Antitumor treatment regimen. “Other” antitumoral regimen included: vinorelbine, temozolomide–irinotecan regimen, sorafenib, regorafenib, sunitinib

Source publication
Article
Full-text available
Background The risk of drug–drug interactions (DDI) has become a major issue in cancer patients. However, data in sarcoma patients are scarce. We aimed to evaluate the frequency and the factors associated with DDI with antitumor treatments, and to evaluate the impact of a pharmacist evaluation before anticancer treatment.Patients and methodsWe perf...

Context in source publication

Context 1
... hundred and two patients were included in this study. One hundred and twenty-two soft-tissue and 80 bone sarcoma patients were included before antitumor treatment: CT (86%) or TKI (14%) (Fig. 1). The median number of comorbidities was 1 (range 0-2). Most of the patients (65%) had advanced-stage or metastatic disease. Patient's baseline characteristics are summarized in Table 1. The median number of drugs per patient was 3 (IQR 2-5), 65 patients (32%) had at least 5 ...